Intercept Pharmaceuticals (ICPT) Given Outperform Rating at Credit Suisse Group

Credit Suisse Group restated their outperform rating on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research report sent to investors on Tuesday.

A number of other analysts have also weighed in on ICPT. BidaskClub lowered shares of Intercept Pharmaceuticals from a buy rating to a hold rating in a report on Friday, October 19th. Needham & Company LLC reissued a hold rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, October 31st. Oppenheimer set a $100.00 price target on shares of Intercept Pharmaceuticals and gave the stock a hold rating in a research note on Wednesday, October 31st. Wedbush set a $220.00 price target on shares of Intercept Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, November 6th. Finally, ValuEngine downgraded shares of Intercept Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, November 12th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Intercept Pharmaceuticals presently has a consensus rating of Buy and an average target price of $153.39.

Intercept Pharmaceuticals stock opened at $111.05 on Tuesday. The company has a quick ratio of 5.98, a current ratio of 5.98 and a debt-to-equity ratio of 3.83. The stock has a market cap of $3.29 billion, a PE ratio of -7.72 and a beta of 1.88. Intercept Pharmaceuticals has a 1-year low of $51.76 and a 1-year high of $133.74.

In other Intercept Pharmaceuticals news, major shareholder S.P.A. Genextra sold 750,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $105.07, for a total transaction of $78,802,500.00. Following the completion of the transaction, the insider now owns 6,095,578 shares of the company’s stock, valued at $640,462,380.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Shapiro sold 474 shares of the firm’s stock in a transaction that occurred on Friday, January 4th. The shares were sold at an average price of $97.48, for a total transaction of $46,205.52. Following the transaction, the insider now directly owns 37,243 shares of the company’s stock, valued at approximately $3,630,447.64. The disclosure for this sale can be found here. Insiders have sold 812,130 shares of company stock valued at $85,159,685 in the last ninety days. Insiders own 4.90% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Intercontinental Wealth Advisors LLC bought a new position in shares of Intercept Pharmaceuticals during the fourth quarter valued at approximately $34,000. Advisor Group Inc. increased its stake in shares of Intercept Pharmaceuticals by 63.5% during the fourth quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 287 shares in the last quarter. Strs Ohio bought a new position in shares of Intercept Pharmaceuticals during the third quarter valued at approximately $126,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Intercept Pharmaceuticals by 14.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,416 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 183 shares in the last quarter. Finally, Chicago Equity Partners LLC bought a new position in shares of Intercept Pharmaceuticals during the third quarter valued at approximately $215,000. 63.48% of the stock is owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Featured Story: How Do You Make Money With Penny Stocks?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply